Global Energy Prize awarded to three scientists from China, USA and Russia
The Prize in the Conventional Energy category went to Jinliang He, chair of High Voltage Engineering Research Institute, professor at China's Tsinghua University. "This honour not only recognises my work alone, but also the collective endeavor of great minds advancing sustainable energy supply. It illuminates a shared vision to power world safely and efficiently. I dedicate this honour toward bridging innovation and advanced technologies for ultra-high voltage transmission systems," said Jinliang He.
For the first time in the history of the Prize, the award in the Non-Conventional Energy category was given to a woman, Yu Huang, professor and department head at the University of California, Los Angeles (USA). She will be awarded for innovations in the field of catalyst development, which significantly improve the profitability, durability and performance of fuel cells.
"I'm deeply honoured and truly humbled to receive this prestigious award. My group develops designer catalysts and we work to bridge the gap between discovery and deployment, turning new materials into working for energy conversion and storage. I have been fortunate enough to work with an extraordinary group of students, postdocs and collaborators. Their creativity and passion are making all of this possible," said Yu Huang.
Russian scientist Vladislav Khomich, head of research at the Institute for Electrophysics and Electric Power of the Russian Academy of Sciences (RAS), won in the New Ways of Energy Application category. He will receive the Prize for outstanding contributions to the development, creation and fundamental research of plasma technologies and pulsed energy.
The names of the laureates of the Prize were selected from a shortlist of 15 scientists from 8 countries. A total of 90 submissions from 44 countries and territories across the world were included in the nomination cycle.
The Committee, headed by the Nobel Peace Prize Laureate Rae Kwon Chung, made the final decision.
"World science is facing global challenges, and it is no exaggeration to say that our ability to quickly solve them will define the future of civilisation. The biggest challenges include the transition to clean technologies for the production, storage and transmission of energy and the search for solutions that can effectively combat global climate change," said Rae Kwon Chung.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
SEOUL, South Korea, July 23, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm. Automating every step of PCR Testing for enhanced efficiency and accuracy CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling. The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments. In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory. STAogra ™ – Real-Time Global Data Integration Empowering Personalized Care Also unveiled at ADLM 2025, STAgora™ is Seegene's statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support. With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making. Expanding Global Collaboration via Technology Sharing and Strategic Partnerships Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe's leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA. "CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we've built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem." Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene. Disclaimer The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.
Korea Herald
3 days ago
- Korea Herald
The 2025 International Congress of Basic Science Opens in Beijing
BEIJING, July 22, 2025 /PRNewswire/ -- The 2025 International Congress of Basic Science (ICBS) officially kicked off on July 13 at the China National Convention Center in Beijing, gathering the world's brightest scientific minds for a landmark two-week conference. The event brings together four Fields Medalists, three Nobel Laureates, and two Turing Award winners, including Shing-Tung Yau and Andrew Chi-Chih Yao, alongside more than 80 academicians and nearly 1,000 researchers from leading global institutions. President of Tsinghua University Li Luming warmly welcomed scientists from around the world. He emphasized that the ICBS has evolved into a premier platform for global scientists to engage in dialogue and deepen collaboration. Tsinghua University will continue to support Professor Shing-Tung Yau's efforts to advance basic science, and will work together with scientists from all countries to strengthen fundamental research, drive scientific and technological innovation, promote socio-economic development, and jointly create a better future for humanity. Shing-Tung Yau — ICBS President, Fields Medalist, and Chair Professor at Tsinghua University — highlighted recent breakthroughs in mathematics, physics, and information science. He believes a new era driven by theoretical breakthroughs and technological innovations may be dawning. Six trailblazing scientists—Samuel C.C. Ting, Steven Chu, David Gross, Robert Tarjan, Shigefumi Mori, and George Lusztig—were honored with the 2025 Basic Science Lifetime Award, the most prestigious award honoring scientists' contributions to fundamental science. The Congress also awarded 118 Frontiers of Science Awards (FSA) across mathematics, physics, and information science, with winners from over 20 countries. Global AI leaders OpenAI and Meta's FAIR team were also among the recipients. The ICBS was initiated by Shing-Tung Yau in 2023 and is held annually with the theme "Advancing Science for Humanity". Over the next two weeks, nearly 1,000 scholars and students—including over 400 world-leading scientists—will gather at the Beijing Institute of Mathematical Sciences and Applications. Over 500 sessions will cover mathematics, physics, and information science and engineering, with a focus on cutting-edge AI research, interdisciplinary innovation, and frontier theoretical breakthroughs. Beyond academic exchange, ICBS emphasized youth engagement through a diverse range of activities, including the "Tsinghua Day" special event on July 19th. ICBS 2025 celebrates international collaboration and academic exchange in global scientific advancement. "Science thrives on collaboration," said Yau. "This is where the next era of discovery begins."
Korea Herald
4 days ago
- Korea Herald
Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster. Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies." Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented:"I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth." About Minaris Advanced Therapies: Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing. Minaris Advanced Therapies is a portfolio company of Altaris. Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit Media Contact:
